Can I Take Quercetin with Losartan?

Why the Quercetin-Losartan Combination Deserves Careful Thought

Quercetin is one of the best-selling flavonoid supplements in North America, marketed for immune support, allergy relief, and cardiovascular health. Losartan is among the most prescribed antihypertensives worldwide. Because patients with hypertension are exactly the population drawn to cardiovascular supplements, the two compounds frequently end up in the same medicine cabinet. That overlap makes understanding their interaction more than a theoretical exercise.

The short answer is that quercetin can meaningfully alter how losartan behaves in the body, and the direction of that alteration is not straightforward. Whether it raises or dampens losartan's blood-pressure effect depends on which metabolic pathway dominates in a given individual. The sections below walk through the mechanisms in enough detail to inform a conversation with your prescriber.

Losartan Is a Prodrug That Depends on CYP2C9

Losartan itself is only weakly active at the AT1 receptor. The liver enzyme CYP2C9 converts roughly 14% of an oral dose into EXP-3174, a metabolite that is 10 to 40 times more potent than the parent drug and accounts for most of losartan's antihypertensive effect. CYP2C9 also contributes to first-pass metabolism of many other drugs, including warfarin and phenytoin.

CYP3A4 handles a parallel metabolic route that produces inactive carboxylic acid metabolites. Both enzymes are expressed in intestinal wall tissue and hepatocytes, so inhibition can occur both pre-systemically (gut) and post-absorptively (liver).

What Quercetin Does to These Enzymes

Quercetin is a recognized inhibitor of CYP2C9 and CYP3A4 in vitro. A widely cited pharmacology review confirmed that quercetin inhibits CYP2C9 with a Ki in the low-micromolar range, a concentration potentially reachable in intestinal tissue after high-dose supplementation. In vitro data from Kimura et al. (2010) in Drug Metabolism and Disposition showed quercetin inhibiting CYP2C9-mediated warfarin hydroxylation at concentrations achievable in the gut wall.

Quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter in the gut wall that limits absorption of many drugs. Reducing P-gp activity could increase losartan's oral bioavailability, raising plasma concentrations of the parent compound before CYP2C9 even acts on it. A 2004 study in the Journal of Pharmacy and Pharmacology demonstrated quercetin-mediated inhibition of P-gp efflux in Caco-2 cell models.

The Two Competing Effects and Why Net Outcome Is Unpredictable

Understanding quercetin's interaction with losartan requires holding two opposing effects simultaneously:

Effect 1: CYP2C9 inhibition reduces EXP-3174 formation. If quercetin slows the conversion of losartan to EXP-3174, less of the potent active metabolite is produced. Blood pressure control could weaken. In a CYP2C9 poor metabolizer (roughly 3 to 5% of European-ancestry individuals carry two loss-of-function alleles), this effect is already maximized at baseline, so quercetin's additional burden matters less. In normal metabolizers, the inhibition could shift them toward a poor-metabolizer phenotype, reducing therapeutic efficacy.

Effect 2: P-gp and CYP3A4 inhibition raises parent-drug exposure. More losartan reaching systemic circulation means higher peak concentrations of the parent compound. The parent drug has mild AT1 activity. Elevated parent-drug levels combined with any residual EXP-3174 could, in theory, produce additive blood-pressure lowering and hypotension risk.

Which Effect Wins?

No published human pharmacokinetic trial has tested these two compounds together in hypertensive patients. Animal data are suggestive but not directly translatable. A rat study published in Food and Chemical Toxicology found that quercetin pretreatment altered the AUC (area under the concentration-time curve) of co-administered drugs metabolized by CYP2C9 and CYP3A4. Choi et al. (2011) in Food and Chemical Toxicology reported quercetin significantly increased the AUC of nifedipine (a CYP3A4 substrate) in rats, suggesting meaningful CYP3A4 inhibition in vivo.

Because losartan's net blood-pressure effect depends on the EXP-3174 to losartan ratio, and quercetin can shift that ratio in either direction depending on which pathway it hits harder, predicting the clinical outcome without monitoring is difficult. The American College of Clinical Pharmacology notes that in vitro Ki values do not always translate directly into clinically significant in vivo interactions, particularly when the inhibitor (quercetin) is taken orally and achieves higher concentrations in intestinal tissue than in plasma. The FDA's guidance on drug-drug interaction studies provides the methodological context for translating in vitro inhibition data to clinical predictions.

The CYP2C9 Genotype Factor

Patients who are CYP2C9 intermediate or poor metabolizers already convert losartan to EXP-3174 less efficiently. Adding quercetin on top may have a smaller metabolic impact for them, but could still affect P-gp-mediated absorption. Conversely, extensive metabolizers who rely heavily on CYP2C9 for their antihypertensive effect may see a more noticeable reduction in blood pressure control. Genetic testing for CYP2C9 variants (e.g., *2 and *3 alleles) is available and may inform this decision for patients on multiple interacting agents. The PharmGKB database at NIH catalogs CYP2C9 variant effects on losartan metabolism.

Pharmacodynamic Layer: Both Compounds Lower Blood Pressure

Beyond enzyme kinetics, quercetin has a direct antihypertensive pharmacodynamic effect. A meta-analysis of 7 randomized controlled trials (N=587) published in the Journal of Nutrition found that quercetin supplementation reduced systolic blood pressure by a mean of 3.04 mmHg (95% CI: 0.76 to 5.32 mmHg, P<0.001) compared with placebo. Serban et al. (2016), Journal of Nutrition, N=587 across 7 RCTs, demonstrated statistically significant SBP reduction with quercetin supplementation.

A 3 mmHg reduction may seem modest, but stacked on top of a therapeutic ARB dose, additive antihypertensive effects become clinically relevant. A patient already achieving a systolic blood pressure of 118 mmHg on 50 mg losartan daily could experience symptomatic hypotension (dizziness, falls, presyncope) when quercetin is added at 1,000 mg/day.

Dose Dependency of Quercetin's Hemodynamic Effect

The Serban meta-analysis noted the blood-pressure reduction was confined to trials using doses at or above 500 mg/day. Lower dietary quercetin intake from food sources (onions, berries, kale) delivers roughly 10 to 30 mg/day, far below the threshold associated with hemodynamic changes. Supplement capsules, typically dosed between 500 mg and 1,500 mg/day, are the relevant clinical concern.

Antihistamine and Anti-Inflammatory Mechanisms

Quercetin's antihistamine properties (mast cell stabilization, inhibition of histamine release) are a common reason patients take it. These mechanisms do not directly interact with losartan's AT1 receptor blockade. The interaction risk is driven by pharmacokinetics and additive blood-pressure effects, not by shared receptor targets.

Clinical Evidence: What Human Data Exist?

Direct clinical trial data on this specific pairing are sparse. No phase I pharmacokinetic study has been registered or published on PubMed for the quercetin-losartan combination as of the last review of this article.

The available evidence comes from three categories:

1. In vitro enzyme studies. These establish that quercetin inhibits CYP2C9 and CYP3A4 at concentrations achievable in intestinal tissue. They do not confirm clinical significance in humans.

2. Animal pharmacokinetic studies. Rodent models show altered drug AUC for CYP2C9/3A4 substrates when quercetin is co-administered. A 2012 study in the European Journal of Drug Metabolism and Pharmacokinetics showed quercetin increased the plasma AUC of amlodipine (another antihypertensive and CYP3A4 substrate) by approximately 56% in rats.

3. Human quercetin-drug interaction case studies and small trials. The best human data come from studies using quercetin alongside warfarin (a CYP2C9 substrate). A controlled study reported in the British Journal of Clinical Pharmacology found quercetin altered warfarin pharmacokinetics in a dose-dependent manner, consistent with CYP2C9 inhibition. Since losartan shares this metabolic pathway, the warfarin data are the closest relevant human analogue. Moon et al. (2008) in the British Journal of Clinical Pharmacology documented quercetin effects on CYP2C9-mediated warfarin metabolism in human subjects.

The absence of a direct losartan trial does not mean the interaction is absent. It means physicians and patients are extrapolating from mechanistic and analogue data, which is a reasonable approach when direct evidence is lacking, as long as monitoring is in place.

Risk Stratification: Who Should Be Most Careful?

Not every patient on losartan faces the same risk from quercetin. The following clinical features raise concern enough to warrant a direct prescriber conversation before starting any quercetin supplement:

Higher-Risk Scenarios

• Current systolic blood pressure consistently at or below 120 mmHg on losartan (little margin before hypotension)
• Losartan dose at or above 100 mg/day (higher doses mean greater absolute exposure changes)
• Concurrent use of other CYP2C9 or CYP3A4 inhibitors (fluconazole, amiodarone, fluvoxamine)
• Known CYP2C9 extensive metabolizer genotype relying heavily on EXP-3174 for blood-pressure control
• History of falls, orthostatic hypotension, or dizziness on antihypertensives
• Planned quercetin dose at or above 500 mg/day

Lower-Risk Scenarios

• Losartan at 25 mg/day with well-controlled but not low blood pressure
• Dietary quercetin only (no concentrated capsules)
• Short-term quercetin use for acute illness (less than 2 weeks)
• CYP2C9 poor metabolizer genotype already relying minimally on EXP-3174

The Natural Medicines database rates the quercetin-losartan interaction as "moderate," advising close monitoring rather than absolute avoidance. The Natural Medicines database interaction checker, accessible via institutional subscription, classifies quercetin as a "moderate" interactor with CYP2C9-metabolized drugs.

Practical Monitoring Protocol If You Are Already Taking Both

If a patient is already combining quercetin supplements with losartan, abruptly stopping either compound also carries risk. Stopping quercetin could partially reverse CYP2C9 inhibition over 1 to 3 days, potentially increasing EXP-3174 production and acutely raising the antihypertensive effect. Abrupt losartan discontinuation risks rebound hypertension.

Step-by-Step Approach

1. Tell your prescriber immediately. Disclose the quercetin brand, dose in milligrams per day, and how long you have been taking it. This is not optional.

2. Home blood-pressure monitoring. Check blood pressure at the same time each morning and evening for at least 1 week after starting or stopping quercetin. Log readings and bring them to your next appointment.

3. Watch for hypotension symptoms. Dizziness on standing, lightheadedness, or fainting warrants same-day contact with your care team, not a wait-and-see approach.

4. Avoid dose-stacking. Do not take quercetin and losartan at exactly the same time without discussing it with your prescriber. Some clinicians suggest a 2-hour separation to reduce gut-wall P-gp inhibition, though human evidence for this specific timing window with this combination is limited.

5. Review the full medication list. If you take warfarin, cyclosporine, or other narrow-therapeutic-index CYP2C9 substrates, quercetin's inhibitory effect becomes higher stakes and may require formal pharmacist review.

The American Heart Association's guidance on complementary and alternative medicine use in cardiovascular patients states: "Patients should be asked about their use of supplements at every visit, because many biologically active compounds interact with prescribed cardiovascular medications in ways that are not immediately obvious." AHA Scientific Statement on complementary medicine in cardiovascular care, Circulation 2005.

What the Prescribing Data Say About Losartan's Metabolic Pathway

Losartan's FDA-approved prescribing information (Cozaar label, Merck) specifically notes that CYP2C9 inhibitors may impair the conversion of losartan to EXP-3174. The label calls out fluconazole as an example. The FDA-approved Cozaar (losartan) label identifies CYP2C9 inhibition as a drug interaction concern and recommends monitoring when CYP2C9 inhibitors are co-administered.

Quercetin is not named in the label because supplements are not subject to the same interaction-screening requirements as FDA-approved drugs. The mechanism, however, applies equally.

The clinical translation is direct: any agent that inhibits CYP2C9, whether it is fluconazole at 200 mg or quercetin at 1,000 mg, reduces EXP-3174 production and could reduce losartan's therapeutic efficacy in extensive metabolizers. At the same time, P-gp inhibition may partially offset this by increasing losartan's oral bioavailability, making prediction without monitoring unreliable.

Losartan Dose Matters

A patient taking 25 mg losartan once daily has a different absolute risk profile than one taking 100 mg twice daily. At higher doses, any percentage-point change in either losartan or EXP-3174 exposure translates into a larger absolute concentration shift. The 100 mg twice-daily patient should have a formal pharmacist or prescriber review before adding any CYP2C9-affecting supplement.

A Note on Quercetin's Own Cardiovascular Evidence

Quercetin has genuine cardiovascular data behind it. Beyond the blood-pressure meta-analysis cited above, a 12-week randomized trial published in the European Journal of Nutrition (N=93 overweight adults) found that 150 mg/day of quercetin reduced LDL cholesterol and plasma oxidized LDL compared with placebo. Egert et al. (2009), European Journal of Nutrition, N=93, found quercetin at 150 mg/day significantly reduced LDL-C in overweight individuals.

This is not a reason to add quercetin without consulting a prescriber. It is context for understanding why patients taking losartan for hypertension or cardiovascular protection may seek out quercetin. The supplement's cardiovascular rationale is real. The interaction with losartan's metabolic pathway is equally real, and both facts need to be part of the clinical conversation.

Summary of the Interaction Mechanism

| Mechanism | Direction | Likely Clinical Effect | |---|---|---| | CYP2C9 inhibition by quercetin | Reduces EXP-3174 formation | Possible reduced antihypertensive efficacy | | CYP3A4 inhibition by quercetin | Reduces inactive metabolite formation | Raises losartan parent-drug AUC | | P-gp inhibition by quercetin | Increases losartan intestinal absorption | Raises losartan parent-drug AUC | | Pharmacodynamic additive effect | Both compounds lower blood pressure | Possible symptomatic hypotension | | Net outcome | Unpredictable without monitoring | Requires blood-pressure tracking |

The net effect in any individual patient depends on their CYP2C9 genotype, the quercetin dose taken, the losartan dose, and concurrent medications. Saying "quercetin always lowers losartan effectiveness" or "quercetin always raises losartan levels" would be an oversimplification. Both are mechanistically possible, which is exactly why individual monitoring is the clinically correct response.

Home blood-pressure readings twice daily for the first 7 days after starting or stopping quercetin supplements, while on any ARB or ACE inhibitor dose, remains the most actionable step available to patients right now.